ClinicalTrials.gg
CompletedNCT00812305Updated Sep 8, 2010

Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects

A Phase 1 interventional study of SKY0402 300mg in healthy patients and SKY0402 300mg in hepatically impaired patients in Pain and Hepatic Impairment, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-09-08.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 146 studies testing bupivacaine in Pain — 19 open to participants now, 19 under way, 3 of them phase 3. Bupivacaine · Pain.

Enrollment
125th of 146
16 · median 63
Started
2009
with 4 others
Phase 1
8 of 146
1 open now
Registered
14th of 146
by date
Lead sponsor
16 of 146
Pacira Pharmaceuticals, Inc

Among the 146 studies testing bupivacaine in Pain, this one is the 125th largest by enrollment, is one of 5 that started in 2009, is one of 8 in phase 1, and was the 14th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 146 studies testing bupivacaine in Pain are open now, in 5 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies testing bupivacaine in Pain, or all of them as a file.
02

Study summary

Review differences between how a healthy person and how a person with liver problems handles the study drug.

Read the detailed description

Evaluate the pharmacokinetic (PK) profile of SKY0402 in subjects with moderate hepatic impairment compared with age-, gender-, and weight-matched control subjects with normal hepatic function.

03

Conditions studied

  • Pain
  • Hepatic Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects:

  • Male or female, ages 18-65 years, inclusive, at Screening. Eligible female subjects of with a nonsterilized male sexual partner must agree to use a hormonal , barrier contraceptive with additional spermicide, or an intrauterine device beginning >30 days prior to study drug administration and continuing until >7 days after the end of the study. Female subjects who are must have been postmenopausal for >1 year if they wish not to use contraceptives. If postmenopausal status is questionable, the subject's follicle stimulating hormone (FSH) level must be checked and must be elevated and consistent with postmenopausal levels (i.e., >40 IU/L); otherwise these subjects must agree to use contraceptives listed above.
  • Able and willing to comply with all study visits and procedures, including returning as scheduled for post-treatment visits.
  • Able to speak, read, and understand the language of the , and any other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to study assessments.
  • Willing and capable of providing written informed consent.

Subjects with Hepatic Impairment:

  • Subjects must have a positive diagnosis of liver cirrhosis (hepatic fibrosis with evidence of either micro- or macro-nodular regeneration) that has been stable for two months and is confirmed by imaging techniques, , or physical signs consistent with a clinical diagnosis of liver cirrhosis (e.g., liver firmness to palpation, splenic enlargement, spider angiomata, palmar erythema, parotid hypertrophy, testicular atrophy, gynecomastia).
  • Subjects must have an impaired but stable hepatic function evidenced by Clinical Assessment Score between 7 and 9 at both screening and baseline.

Control Subjects with Normal Hepatic Function:

  • Subjects must be in general good health as determined by past medical history, physical examination, vital signs, , Chest X-Ray (CXR), and laboratory tests at screening.
  • Subjects should be matched to a hepatically impaired subject in gender, age (±15%) and weight (±20%).

Exclusion criteria

Exclusion Criteria:

All Subjects

  • A history of to amide type local anesthetics.
  • Pregnancy, nursing, or planning to become pregnant during the course of the study.
  • Body weight less than 60 kg (\~132 lbs) or more than 120 kg (\~264 lbs).
  • of less than 18 or more than 35 kg/m2
  • Significant acute, new onset illness (e.g., flu, gastroenteritis) within two weeks prior to study treatment administration.
  • haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, neurological, or psychiatric disease that may pose a significant safety risk or diminish subject's ability to undergo all study procedures and assessments
  • History of status, including a positive (ELISA and Western blot) test result.
  • Evidence of active alcohol or drug abuse as indicated by the tests conducted during the screening or baseline evaluations; subject must state they are willing to remain alcohol and drug free for three weeks after study drug administration.
  • Use of ASA within 10 days prior to study drug administration.
  • Use of Lidocaine, mepivacaine, etidocaine, ropivacaine, and any amide-type anesthetics in any form within 5 elimination half-lives.
  • Use of any local anesthetic within 3 days prior to study drug administration.
  • Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
  • Any condition that, in the opinion of the Investigator, renders a subject unsuitable for participation in the study. NOTE: A specific rationale must be provided and documented for excluding all prospective subjects deemed unsuitable for the study.

Subjects with Hepatic Impairment:

  • Clinically significant abnormal findings other than hepatic impairment.
  • Clinical evidence of severe ascites, as judged by the investigator.
  • History of surgical portosystemic shunt.
  • Fluctuating or rapidly deteriorating hepatic function as indicated by recent history or by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
  • On active Hepatitis treatment with Interferon or other excluded medications (see Appendix 4)

Control Subjects with Normal Hepatic Function:

  • Prohibited prescription medications within 14 days prior to dosing; see Appendix 4 for specific medications.
  • History or presence of liver disease or liver injury as indicated by an abnormal liver function profile such as , SGPT, GGT, alkaline phosphatase, or serum .
  • as indicated by positive HBs Ag, or as indicated by positive anti-HCV result.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Low dose in healthy patients

    Drug: SKY0402 300mg in healthy patients

  • Experimental
    Low dose in hepatically impaired patients

    Drug: SKY0402 300mg in hepatically impaired patients

Interventions

  • SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients

    Also known as: Healthy and Hepatic Impaired subjects will receive SKY0402.

  • SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients

    Also known as: Healthy and Hepatic Impaired subjects will receive SKY0402.

06

What researchers measure

Primary outcomes

  1. Serum plasma concentration of SKY0402

    Time frame: Multiple through 96 hours

07

Study locations

1 site
  • MTZ Clinical Research
    Warsaw, Poland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2008
First posted
Dec 22, 2008
Start
Jan 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results delay requested
Aug 25, 2010
Last update
Sep 8, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00812305
First posted
Dec 22, 2008
Start date
Jan 2009
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Sep 8, 2010

Study contacts

Janusz Rupinski
study director · Pharm-Olam International Polska

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion